baker
Microdosed LSD: Finally A Breakthrough For Alzheimer’s Disease?
[Stage 1 Clinical Trials]
-
Eleusis is investigating the anti-inflammatory potential of psychedelics as medicines, specifically the application of sub-perceptual doses of LSD in halting the progression of Alzheimer’s disease at its earliest detectable stage.
-
When you combine all of the effects which LSD or other psychedelics have been observed to have, in vitro, in animal models, and in patients, they check all the boxes for an attractive multi-target drug candidate with the potential to halt the progression of Alzheimer’s disease.
-
we chose LSD first because it has the best safety profile, it hit all the targets in Alzheimer's disease, and we wanted to demonstrate the viability of transforming psychedelics into medicine at sub-perceptual dose levels.
Sauce: https://www.forbes.com/sites/abbierosner/2020/02/21/microdosed-lsd-may-finally-be-the-breakthrough-for-alzheimers-disease/#2a9a9a9553a8
Company: https://www.eleusisltd.com/